COVID-19 VACCINATION RESPONSES WITH DIFFERENT VACCINE PLATFORMS IN PATIENTS WITH INBORN ERRORS OF IMMUNITY

ERRA, LORENZO; URIARTE, IGNACIO; COLADO, ANA; PAOLINI, MARÍA VIRGINIA; SEMINARIO, GISELA; FERNANDEZ, JULIETA; TAU, LORENA; BERNATOWIEZ, JULIANA; MOREIRA, ILEANA; VISHNOPOLSKA, SEBASTIÁN; RUMBO, MARTÍN; CASSARINO, CHIARA; VIJODITZ, GUSTAVO; LOPEZ, ANA LAURA; CURCIARELLO, RENATA; RODRIGUEZ, DIEGO; RIZZO, GASTÓN; FERREYRA, MALENA; FERREYRA MUFARREGUE, LEILA ROMINA; BADANO, MARÍA NOEL; PEREZ MILLAN, MARIA INES; MARIA FLORENCIA QUIROGA; BARÉ, PATRICIA; IBAÑEZ, ITATÍ; POZNER, ROBERTO; BORGE, MERCEDES; DOCENA, GUILLERMO; BERZRODNIK, LILIANA; ALMEJUN, MARÍA BELÉN

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Patients with Inborn Errors of Immunity (IEI) in Argentinawere encouraged to receive licensed Sputnik, AstraZeneca,Sinopharm, Moderna, and Pfizer vaccines, eventhough most of the data on available vaccines comesfrom trials conducted in healthy individuals. We aimed toevaluate the safety and immunogenicity of the differentvaccines in IEI patients in Argentina. The study cohort includedadults and pediatric IEI patients (n=118) and agematchedhealthy controls (HC) (n=37). Samples werecollected before, 28+/-3 days after the first and the seconddose of the vaccine. B-cell response was evaluatedby measuring IgG anti-Spike(S)/RBD and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodieswere also assessed with an alpha-S protein-expressingpseudo-virus assay. The T-cell response was analyzedby IFN-γ secretion on S or N-stimulated PBMC by ELISPOTand the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry.No moderate/severe vaccine-associated adverse eventswere observed. Regarding the antibody response, anti-S/RBD titers showed significant differences in both pediatricand adult IEI patients versus the age-matched HCcohort (p